Search
for
Sort by
Research 30 of 1000+
- A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice
- Estimating the Contribution of the Prostate to Blood Dihydrotestosterone
- Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients
- Trypanocidal Effect of Isotretinoin through the Inhibition of Polyamine and Amino Acid Transporters in Trypanosoma cruzi
- Alopecia areata susceptibility variant identified by MHC risk haplotype sequencing reproduces symptomatic patched hair loss in mice
- Alopecia areata susceptibility variant in MHC region impacts expressions of genes contributing to hair keratinization and is involved in hair loss
- Efficacy and safety of trastuzumab deruxtecan in the treatment of HER2-low/positive advanced breast cancer: a single-arm meta-analysis
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities
- Long-Term Differential Changes in Mouse Intestinal Metabolomics after γ and Heavy Ion Radiation Exposure
- Sox9 regulates melanocytic fate decision of adult hair follicle stem cells
- Dahuang-Gancao Decoction Ameliorates Testosterone-Induced Androgenetic Alopecia in Mice
- Apoptotic dysregulation mediates stem cell competition and tissue regeneration
- A novel microparticle based formulation for topical delivery of FOL-005, a small peptide
- SUN-005 Hirsutism Due to Bilateral Leydig Cell Tumors
- 128 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a potent novel peptide hair growth promoter, FOL-005
- 201 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a new potent novel inhibitor of human hair growth, FOL-005
- 695 Using MALDI-MSI analysis to study distribution of FOL-005, a potent, novel inhibitor of human hair growth, after subcutaneous injection in mice
- Alfatradiol (0,025 %) - Eine wirksame und sichere Therapieoption zur Behandlung der androgenetischen Alopezie bei Frauen und Männern
- The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
- Microneedling Plus Clobetasol Propionate 0.05% Cream versus Clobetasol Propionate 0.05% Cream Alone in the Treatment of Alopecia Areata
- Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis
- Effect of dutasteride 0.5 mg/d in men with androgenetic alopecia recalcitrant to finasteride
- The Efficacy and Safety of 17α-Estradiol (Ell-Cranell® alpha 0.025%) Solution on Female Pattern Hair Loss: Single Center, Open-Label, Non-Comparative, Phase IV Study
- Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind Study of 119 Patients
- Efficacy of topical tacrolimus 0.1% and clobetasol propionate 0.05% in the treatment of alopecia areata
- Dermal safety comparison of 0.05% desonide cream and 1.0% hydrocortisone cream
- Eruptive vellus hair cyst: Treatment with topical tretinoin 0.025% cream
- Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
- A Randomized, Double-Blind, Placebo and Active Controlled Phase II Study to Evaluate the Safety and Efficacy of Novel Dutasteride Topical Solution (0.01%, 0.02%, and 0.05% w/v) in Male Subjects With Androgenetic Alopecia
- COMPARATIVE EFFICACY OF TOPICAL CLOBETASOL PROPIONATE 0.05% OINTMENT AND TOPICAL TACROLIMUS 0.1% OINTMENT IN THE TREATMENT OF ALOPECIA AREATA